NORD Launches New Blog

NORD Launches New Blog

10.22.12 | By

I've been a contributor on our very own blog, the Catalyst, for a year now. I try my best to write interesting blog posts that pertain to the incredible work biopharmaceutical scientists do to help improve patient care in the U.S. and around the world. Blog writing is still somewhat new to me but I have thoroughly enjoyed writing about subject matter that touches millions of patients' lives, including my own.

When I learned that the National Organization for Rare Disorders (NORD) launched its own blog last week, I was eager to check it out. One particular area NORD blog writers will cover includes "innovative efforts by patients and patient organizations to encourage the development of treatments for rare diseases."

The launch of the NORD blog couldn't be more timely for the nearly 30 million Americans suffering from rare diseases. It provides an opportunity for the greater community to contribute to an online dialogue about the impact rare diseases has on their lives or the lives of their loved ones. And it gives NORD a sounding board to inspire and educate others about the important advocacy work they do for the patients they represent.

NORD shares our mission of advancing and improving patients' lives and in many ways, we consider them partners in our innovation journey to hope - hope for a treatment or cure for all the rare disorders that exist in the world today (there are nearly 7,000 rare disorders in the U.S. alone).

Today, with more than 400 medicines in development by biopharmaceutical research companies to help treat patients with rare diseases, we have made it far in that journey. What's more, since 1983, more than 350 medicines have been approved by the Food and Drug Administration to treat patients with rare disorders.

Importantly, by utilizing online venues such as blogs, we can all continue to do what we do best and that is advocate for the millions of patients who suffer from disease and provide hope for those who need it the most.

More On PhRMA — powered by PhRMApedia


Cost in Context